Antiplatelet Agents for Stroke Prevention

Neurotherapeutics

Volumn 8, Issue 3, 2011, Pages 475-487

  Yip, Samuel ^a   Benavente, Oscar ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiplatelets; Aspirin; Clinical trials; Clopidogrel; Dipyridamole; Prevention; Stoke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; DIPYRIDAMOLE; IRBESARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SIMVASTATIN; WARFARIN;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LARGE ARTERY ATHEROSCLEROSIS; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE;

EID: 79960761162     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0060-2     Document Type: Review

References (45)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004; 62: 2015-2020.
3. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901-2906.
4. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39: 1647-1652.
5. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617.
6. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-258.
7. Humbert M, Nurden P, Bihour C, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996; 16: 1532-1543.
8. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl 1983; 4: 39-46.
9. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-573.
10. Petty GW, Brown RD Jr., Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 1062-1068.
11. Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Alvarez-Sabin J. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 2007; 38: 3225-3229.
12. CAST: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349: 1641-1649.
13. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19, 435 patients with acute ischemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-1581.
14. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31: 1240-1249.
15. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969.
16. Wang Y, Johnston SC. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010; 160: 380-386.
17. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60: 197-199.
18. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
19. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
21. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
22. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
23. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325: 445-453.
24. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379-1387.
25. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42: 857-865.
26. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451.
27. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6: 115-124.
28. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39: 1358-1363.
29. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
30. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
31. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
32. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
33. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
34. Kent DM, Thaler DE. Stroke prevention-insights from incoherence. N Engl J Med 2008; 359: 1287-1289.
35. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
36. Ariesen MJ, Algra A, Kappelle LJ. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006; 37: 134-138.
37. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316.
38. Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489-497.
39. Benavente O. Antithrombotic therapy in small subcortical strokes (lacunar infarcts). Adv Neurol 2003; 92: 275-280.
40. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
41. Benavente OR, White CL, Pearce L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011; 6: 164-175.
42. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug "resistance." Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009; 6: 273-282.
43. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. NEJM 2001; 345: 1809-1817.
44. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug- drug interaction. Circulation 2003; 107: 32-37.
45. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel- atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.